{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:50:24Z","timestamp":1782208224468,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03534-2","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:29:01Z","timestamp":1776497341000},"page":"2961-2976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Faricimab in Treatment-Na\u00efve nAMD: Regional UK Real-World Experience"],"prefix":"10.1007","volume":"43","author":[{"given":"Ian","family":"Pearce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Dinah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Vardarinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwyn","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"16","key":"3534_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169424","volume":"23","author":"S Liberski","year":"2022","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. 2022;23(16):9424.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3534_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/APO.0000000000000291","volume":"9","author":"A Samanta","year":"2020","unstructured":"Samanta A, Aziz AA, Jhingan M, Singh SR, Khanani AM, Chhablani J. Emerging therapies in neovascular age-related macular degeneration in 2020. Asia-Pac J Ophthalmol. 2020;9(3):250\u20139.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"1","key":"3534_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12886-018-0824-0","volume":"18","author":"P Tyagi","year":"2018","unstructured":"Tyagi P, Juma Z, Hor YK, Scott NW, Ionean A, Santiago C. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from ranibizumab to aflibercept. BMC Ophthalmol. 2018;18(1):148.","journal-title":"BMC Ophthalmol"},{"key":"3534_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031170","author":"A Pugazhendhi","year":"2021","unstructured":"Pugazhendhi A, Hubbell M, Jairam P, Ambati B. Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22031170.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3534_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/eye.2014.103","volume":"28","author":"A Rees","year":"2014","unstructured":"Rees A, Zekite A, Bunce C, Patel PJ. How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration? Eye (Lond). 2014;28(7):832\u20137.","journal-title":"Eye (Lond)"},{"issue":"3","key":"3534_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41433-022-01933-7","volume":"37","author":"K Brown","year":"2023","unstructured":"Brown K, Bunce C, Onabanjo O, Strong SA, Patel PJ. Is preventable sight loss truly preventable? An exploration of a public health indicator for sight loss due to age-related macular degeneration in England. Eye (Lond). 2023;37(3):516\u201323.","journal-title":"Eye (Lond)"},{"issue":"9","key":"3534_CR7","volume":"14","author":"H Vyawahare","year":"2022","unstructured":"Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14(9):e29583.","journal-title":"Cureus"},{"issue":"9","key":"3534_CR8","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144\u201367.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3534_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","volume":"120","author":"JW Miller","year":"2013","unstructured":"Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106\u201314.","journal-title":"Ophthalmology"},{"issue":"1","key":"3534_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5301\/ejo.5000880","volume":"27","author":"D Veritti","year":"2017","unstructured":"Veritti D, Sarao V, Parravano M, Arias L, Varano M, Lanzetta P. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study. Eur J Ophthalmol. 2017;27(1):74\u20139.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"3534_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/IAE.0b013e31826d8ff4","volume":"33","author":"D Veritti","year":"2013","unstructured":"Veritti D, Macor S, Menchini F, Lanzetta P. Effects of VEGF inhibition on retinal morphology, neovascular network size, and visual acuity in patients with vascularized pigment epithelium detachment because of occult choroidal neovascularization. Retina. 2013;33(5):982\u20139.","journal-title":"Retina"},{"key":"3534_CR12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2147\/DMSO.S214098","volume":"12","author":"KL Spooner","year":"2019","unstructured":"Spooner KL, Guinan G, Koller S, Hong T, Chang AA. Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia. Diabetes Metab Syndr Obes. 2019;12:1913\u201321.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"3534_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye Lond. 2020;34(5):802\u20134.","journal-title":"Eye Lond"},{"key":"3534_CR14","doi-asserted-by":"crossref","unstructured":"Veritti D, Sarao V, Gonfiantini M, Rubinato L, Lanzetta P. Faricimab in neovascular AMD complicated by pigment epithelium detachment: an AI-assisted evaluation of early morphological changes. Ophthalmol Ther. 2024;13:2813-24.","DOI":"10.1007\/s40123-024-01005-x"},{"key":"3534_CR15","doi-asserted-by":"crossref","unstructured":"Wallsh JO, Gallemore RP. Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells. 2021;10(5):1049.","DOI":"10.3390\/cells10051049"},{"issue":"5","key":"3534_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35(5):1305\u201316.","journal-title":"Eye Lond"},{"issue":"10326","key":"3534_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"4","key":"3534_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, et al. TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1(4):100076.","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"3534_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M. Faricimab: first approval. Drugs. 2022;82(7):825\u201330.","journal-title":"Drugs"},{"key":"3534_CR20","unstructured":"European Medicines Agency. Vabysmo. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vabysmo. Accessed 14 Oct 2024"},{"key":"3534_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/OPTH.S503060","volume":"19","author":"MR Barakat","year":"2025","unstructured":"Barakat MR, Kwong HM Jr, Marcon G, O\u2019Leary OE, Paris LP, Schneider P, et al. Human factors studies to assess the usability of the faricimab prefilled syringe. Clin Ophthalmol. 2025;19:395\u2013406.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"3534_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14(1):11681.","journal-title":"Sci Rep"},{"issue":"12","key":"3534_CR23","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1007\/s12325-022-02326-8","volume":"39","author":"H Mehta","year":"2022","unstructured":"Mehta H, Nguyen V, Barthelmes D, Pershing S, Chi GC, Dopart P, et al. Outcomes of over 40,000 eyes treated for diabetic macula edema in routine clinical practice: a systematic review and meta-analysis. Adv Ther. 2022;39(12):5376\u201390.","journal-title":"Adv Ther"},{"issue":"3","key":"3534_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100442","volume":"4","author":"R Guymer","year":"2024","unstructured":"Guymer R, Bailey C, Chaikitmongkol V, Chakravarthy U, Chaudhary V, Finger RP, et al. Rationale and design of VOYAGER: long-term outcomes of faricimab and port delivery system with ranibizumab for neovascular age-related macular degeneration and diabetic macular edema in clinical practice. Ophthalmol Sci. 2024;4(3):100442.","journal-title":"Ophthalmol Sci"},{"key":"3534_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, Gentile B, Chi GC, Mirt M, et al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence. 2022;16:587\u2013604.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3534_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40123-024-01060-4","volume":"14","author":"F Ziemssen","year":"2025","unstructured":"Ziemssen F, Sylvanowicz M, Amoaku WM, Aslam T, Eldem B, Finger RP, et al. Improving clinical management of diabetic macular edema: insights from a global survey of patients, healthcare providers, and clinic staff. Ophthalmol Ther. 2025;14(1):229\u201346.","journal-title":"Ophthalmol Therapy"},{"issue":"17","key":"3534_CR27","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023;37(17):3574\u201381.","journal-title":"Eye (Lond)"},{"key":"3534_CR28","unstructured":"National Institute for Health and Care Excellence. Faricimab for treating wet age-related macular degeneration 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/ta800\/chapter\/1-Recommendations. Accessed 14 Oct 2024."},{"key":"3534_CR29","unstructured":"Electronic Medicines Compendium. Vabysmo 120 mg\/mL solution for injection 2024. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/13741\/smpc. Accessed 14 Oct 2024."},{"issue":"4","key":"3534_CR30","doi-asserted-by":"publisher","first-page":"e920","DOI":"10.1111\/aos.15014","volume":"100","author":"M Niedzwiecki","year":"2022","unstructured":"Niedzwiecki M, Hunt A, Nguyen V, Mehta H, Creuzot-Garcher C, Gabrielle PH, et al. 12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry. Acta Ophthalmol. 2022;100(4):e920\u20137.","journal-title":"Acta Ophthalmol"},{"issue":"15","key":"3534_CR31","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye. 2023;37(15):3282\u20139.","journal-title":"Eye"},{"key":"3534_CR32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/OPTH.S463624","volume":"18","author":"NQX Quah","year":"2024","unstructured":"Quah NQX, Javed K, Arbi L, Hanumunthadu D. Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2024;18:1479\u201390.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"3534_CR33","first-page":"4905","volume":"65","author":"D Varma","year":"2024","unstructured":"Varma D, Talks J, de Salvo G, Patel PJ, De Silva SR, Gale R, et al. Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD. Invest Ophthalmol Vis Sci. 2024;65(7):4905.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3534_CR34","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.2147\/OPTH.S468458","volume":"18","author":"D Modeste","year":"2024","unstructured":"Modeste D, Stewart C, Premanandhan H, Awad MH, Williams GS. Evaluating faricimab in treatment-naive neovascular age related macular degeneration: a retrospective analysis of real-world data. Clin Ophthalmol. 2024;18:2821\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"3534_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100744","volume":"5","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Guymer R, Artignan A, Downey A, Singh RP. Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: a\u00a0scoping review. Ophthalmol Sci. 2025;5(4):100744.","journal-title":"Ophthalmol Sci"},{"key":"3534_CR36","doi-asserted-by":"crossref","unstructured":"Scampoli A, Carl\u00e0 MM, Grieco G, Governatori L, Catalani R, Rizzo S, et al. One-year functional and structural results of faricimab for treatment-na\u00efve neovascular age related macular degeneration: an OCT angiography study. Graefes Arch Clin Exp Ophthalmol. 2025;263:2219-26.","DOI":"10.1007\/s00417-025-06849-y"},{"issue":"8","key":"3534_CR37","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen S-J, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"key":"3534_CR38","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.2147\/OPTH.S532179","volume":"19","author":"K Robinson","year":"2025","unstructured":"Robinson K, Cooper SJ, Persaud S, Frederick JL, Singh RP. Discordance among patients and ophthalmologists regarding the burden of intravitreal injections. Clin Ophthalmol. 2025;19:2637\u201345.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"3534_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous. 2024;10(1):5.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"3534_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82746-4","volume":"15","author":"HY Han","year":"2025","unstructured":"Han HY, Park SM, Lee JH, Kim CG, Kim JW, Cho HJ, et al. Outcomes and predictive factors for fluid resolution following three loading injections of faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Sci Rep. 2025;15(1):938.","journal-title":"Sci Rep"},{"key":"3534_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102915","volume":"78","author":"BE Wilson","year":"2024","unstructured":"Wilson BE, Booth CM. Real-world data: bridging the gap between clinical trials and practice. EClinicalMedicine. 2024;78:102915.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"3534_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41433-024-03487-2","volume":"39","author":"A Patwardhan","year":"2025","unstructured":"Patwardhan A, Ali N, Law S. Intravitreal faricimab in treatment-na\u00efve neovascular age-related macular degeneration: real-world outcome of 12-week extension after the loading dose from a UK centre. Eye (Lond). 2025;39(4):766\u201370.","journal-title":"Eye (Lond)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03534-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03534-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03534-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:20:58Z","timestamp":1782206458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03534-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3534"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03534-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ian Pearce: Received consulting\/lecture fees from AbbVie, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Novartis, and Roche\/Genentech;\u00a0Christiana Dinah: Received consulting fees from AbbVie, Apellis, Astellas, Boehringer Ingelheim, Eyepoint Pharmaceutical, Johnson and Johnson, Ocular Therapeutics, and Roche; reported speaker fees from Apellis, Bayer, Heidelberg Engineering, Roche, and Topcon;\u00a0Louise Downey: Attendance at advisory boards support from Alimera, Allergan, Bayer, Novartis, Outlook Therapeutics, and Roche, research funding support from Alimera, Allergan, Bayer, Novartis, and Roche, travel support from Allergan, Bayer, Novartis, and Roche; Ashish Patwardhan: Attendance at advisory boards\/received lecture fees\/travel support from AbbVie, Alimera Sciences, Bayer, Novartis, and Roche;\u00a0Athanasios Vardarinos: Attendance at advisory boards\/received lecture fees\/travel support from, Bayer, Biogen, Novartis and Roche;\u00a0Gwyn Williams: No conflicts of interest declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study was locally registered as a retrospective audit where patient identifiable data were omitted, therefore ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}